Perry Carter

Mr. Perry Carter

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2020 in Eye
Verified
Journal Article
Closed access
PDF file
PCPerry Carter
Perry Carter
AGArabella Gordon-Reid
Arabella Gordon-Reid
FSFatima Shawkat
Fatima Shawkat
JSJay Self
Jay Self

28 March 2025 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
SBSteffen Bayer
Steffen Bayer
DGDaniel Garillo
Daniel Garillo
MPMarion Penn
Marion Penn
MCMaria Chorozoglou
Maria Chorozoglou
Sally BrailsfordSally Brailsford
Sally Brailsford
JSJay Self
Jay Self
Background/objectives: Visual Electro-Diagnostic Testing (EDTs) are a highly specialised service in the NHS. The high cost of tests and a paucity of trained visual electrophysiologists has resulted in very few services across the UK and, when combined with increasing patient backlogs, has caused significant travel burden and variable waiting times. Here, we study the potential for impact on patients and services by adding a screening step to traditional referral pathways using an Electroretinogram (ERG) test from a relatively inexpensive, portable, hand-held EDT device; the RETeval® (LKC technologies, Gaithersburg, MD, USA). Subjects/methods: We model a large regional-referral EDT service using Discrete Event Simulation (DES) modelling based on retrospective patient data and published best evidence for the device. We evaluate the potential impact that adding the screening step in referral pathways could have on patient waiting times should the device prove to be safe and useable in clinical practice. Results: We demonstrate that should the RETeval® ERG be safe and useable in real-world clinical practice, it has the potential to significantly reduce patient waiting times by avoiding lab-based EDT assessment for up to 45% of patients. We also show that the impact on services and patients is likely to be resilient to realistic changes in referral numbers, sensitivity/specificity of the device and changes in clinical capacity. Conclusions: This work demonstrates that a RETeval® ERG screening step, performed at the point of referral, has the potential to result in significantly reduced EDT waiting lists through fewer patients requiring lab-based EDT assessment and that DES modelling is a useful tool in making this assessment. However, many questions remain about using the device in the real-world setting for this purpose. Future studies are needed to assess its sensitivity/specificity, test/retest variability, changes in referral patterns due to the device, useability, acceptability to patients and importantly, the consequences of screening errors. Our work, using only retrospective data and a DES model, shows that using the device as an ERG screening tool warrants further investigation due to the potential impact on both patients and clinical services.

30 October 2020 in Eye
Verified
Journal Article
Closed access
PDF file
PCPerry Carter
Perry Carter
AGArabella Gordon-Reid
Arabella Gordon-Reid
FSFatima Shawkat
Fatima Shawkat
JSJay Self
Jay Self

30 May 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
EKEloise Keeling
Eloise Keeling
PCPerry Carter
Perry Carter
AMAbdi Malik Musa
Abdi Malik Musa
SFShawkat, Fatima
Shawkat, Fatima
HLHelena Lee
Helena Lee
JSJay Self
Jay Self
Background: Visual evoked potentials (VEPs) are used to detect chiasmal misrouting associated with albinism. However, VEPs are only performed in specialist centres and typically have long waiting lists. The portable electrophysiology device RETeval® shows promise as a clinical screening tool across a range of ophthalmic conditions. Here, we explore its utility in detecting chiasmal abnormalities associated with albinism. Methods: Flash VEPs were recorded on the RETeval® and by standard ISCEV techniques for 27 patients with suspected albinism and 40 control patients as part of routine appointments. We retrospectively investigated the agreeability between the two methods. The amplitude/latency of the main component was measured for standard VEPs whilst a correlation value of interhemispheric difference was calculated for the RETeval® data. Results: We demonstrate a significant difference between albinism patients and controls (p < 0.001) with respect to the interhemispheric difference identified by the RETeval®. By applying a threshold of 0.001865 to the correlation value, the RETeval® detected chiasmal misrouting in all 27 patients with albinism and had 97% agreeability to standard testing. Conclusions: This study shows the potential of using the RETeval® as a clinical tool for the diagnosis of chiasmal anomalies in albinism. The RETeval® has significant time/cost savings which could hasten diagnoses.